Tonghua Dongbao Pharmaceutical (600867.SH): Summary Report of Phase IIa Clinical Trial of Gout Dual Target Inhibitor (THDBH151 Tablets) Completed

Tonghua Dongbao Pharmaceutical (600867.SH) announced that its wholly-owned subsidiary, Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd., has received the approval notice for the clinical trial of gout dual-target XO/URAT1 inhibitor (THDBH151 tablets) issued by the National Medical Products Administration. The company has completed a key Phase IIa clinical trial and obtained a summary report of the clinical trial, with research results showing that the main endpoint target has been achieved. The results of the Phase IIa clinical trial show that THDBH151 tablets, when administered once daily, have a precise short-term therapeutic effect on lowering uric acid levels, good safety and tolerability, low gout attack rates, and a feasible dosage regimen. Based on its favorable benefit-risk ratio, the applicant is progressing with related research work according to plan.